<code id='B9876EA8B5'></code><style id='B9876EA8B5'></style>
    • <acronym id='B9876EA8B5'></acronym>
      <center id='B9876EA8B5'><center id='B9876EA8B5'><tfoot id='B9876EA8B5'></tfoot></center><abbr id='B9876EA8B5'><dir id='B9876EA8B5'><tfoot id='B9876EA8B5'></tfoot><noframes id='B9876EA8B5'>

    • <optgroup id='B9876EA8B5'><strike id='B9876EA8B5'><sup id='B9876EA8B5'></sup></strike><code id='B9876EA8B5'></code></optgroup>
        1. <b id='B9876EA8B5'><label id='B9876EA8B5'><select id='B9876EA8B5'><dt id='B9876EA8B5'><span id='B9876EA8B5'></span></dt></select></label></b><u id='B9876EA8B5'></u>
          <i id='B9876EA8B5'><strike id='B9876EA8B5'><tt id='B9876EA8B5'><pre id='B9876EA8B5'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:948
          Cigna Healthcare's logo on a phone
          Adobe

          CVS Health viewed Amy Bricker as a potential CEO. But she won’t be going to the health care conglomerate anytime soon.

          A federal appeals court has ruled Bricker, a former high-ranking executive at Cigna, cannot jump to CVS because it would violate her noncompete agreement that she signed while at Cigna. The appeals court’s decision backs up what a district court had previously ruled.

          advertisement

          The case is a prominent example of why the health care industry, and corporate America writ large, does not want noncompetes to go away. In April, the Federal Trade Commission approved a nationwide ban on most such agreements, which prevent workers from moving to other jobs, but companies and corporate lobbying groups have already sued to squash the ban.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Experts study whether long Covid risk adds up with each reinfection
          Experts study whether long Covid risk adds up with each reinfection

          AstudyfromZiyadAl-Aly,clinicalepidemiologistatWashingtonUniversityinSt.Louis,showedthatvaccinationap

          read more
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more

          Updated Covid vaccine has 54% effectiveness, new study suggests

          AhealthcareworkerfillsasyringewithPfizer'sCovid-19vaccine.LynneSladky/APNewdatareleasedThursdaybythe